Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Drug Analysis Methods01:26

Therapeutic Drug Monitoring: Drug Analysis Methods

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Nursing Process for Patient and Caregiver Teaching III: Evaluation and Documentation01:20

Nursing Process for Patient and Caregiver Teaching III: Evaluation and Documentation

Evaluation of the teaching process enables the nurse to determine if the patient's learning needs were met and if training was effective. If the expected outcomes are not met, the care plan is revised, and additional education or reinforcement is provided. Nurses can ask questions after the session or obtain feedback to assess the patient's understanding of the topic.
Nurses can use several methods to evaluate patient outcomes. For example, oral questions can assess cognitive learning, patient...
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Travel barriers to amyloid-targeting infusion access among older adults.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

Removal of Empty AAV Capsids to Undetectable Levels Using Orthogonal Purification Steps.

Biotechnology and bioengineering·2026
Same author

Identification of cognitive impairment using the Lancet Commission's risk factors and Medicare administrative data.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Community-Based Physician Attitudes Related to the Diagnosis and Treatment of Early Alzheimer's Disease in the United States.

American journal of Alzheimer's disease and other dementias·2026
Same author

Target product profiles for treatments to delay or prevent symptomatic Alzheimer's disease.

Nature medicine·2026
Same journal

<i>Corrigendum to:</i> Identifying and Measuring Caregiver Burdens: A Scoping Review.

Population health management·2026
Same journal

When Administrative Requirements Shape Access: Medicaid Work Requirements and Mental Health Care.

Population health management·2026
Same journal

Screening for and Addressing Social Determinants of Health at Transitions of Care.

Population health management·2026
Same journal

When Sleep Hurts the Joints: Longitudinal Associations of Sleep Quality and Duration with Incident Arthritis in the English Longitudinal Study of Aging.

Population health management·2026
Same journal

It's Time to Build the Infrastructure that Makes Health Possible: Formalizing Accountable Communities for Health.

Population health management·2026
Same journal

Point-of-Care A1C and Time from Test to Communication of Results in Primary Care.

Population health management·2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Testing the DMAA's recommendations for disease management program evaluation.

Seth Serxner1, Soeren Mattke, Sarah Zakowski

  • 1Mercer, Los Angeles, California, USA.

Population Health Management
|October 24, 2008
PubMed
Summary
This summary is machine-generated.

Evaluating disease management (DM) programs requires standardized methods. Differences in cost assumptions, exclusions, and baseline periods significantly impact financial savings projections, hindering comparability.

Related Experiment Videos

Last Updated: Jun 28, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Area of Science:

  • Health Economics
  • Health Services Research
  • Program Evaluation

Background:

  • Disease management (DM) programs aim to reduce healthcare costs.
  • Varied evaluation methodologies complicate the assessment of DM program financial savings.

Purpose of the Study:

  • To compare financial savings projections of DM programs using different evaluation methods.
  • To analyze the impact of specific assumptions (cost growth, exclusions, baseline length) on savings estimates.

Main Methods:

  • Pre-post study design utilizing claims and enrollment data from two large employers (2001-2005).
  • Analysis focused on group-level averages and DM-only intervention impact.
  • Investigated the influence of varying assumptions on health cost growth, high-cost exclusions, and baseline period length.

Main Results:

  • Trend estimates and baseline period length significantly affected program impact estimations.
  • Exclusion criteria also demonstrated a notable influence on financial savings projections.
  • Methodological differences substantially alter DM program financial outcome assessments.

Conclusions:

  • Standardized evaluation methodologies are crucial for consistent and reliable DM program assessment.
  • Inconsistent evaluation practices impede the comparison of program effectiveness and trust in results.
  • Establishing uniform evaluation standards is essential for accurate financial savings projections.